Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...

These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.

Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be ...

The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. This story was originally published on BioPharma Dive. To ...

Abemaciclib plus endocrine therapy significantly improved overall survival, IDFS, and DRFS in HR-positive, HER2-negative, node-positive early breast cancer. Adjuvant abemaciclib (Verzenio; Eli Lilly) ...

Adding the CDK4/6 inhibitor abemaciclib to endocrine therapy significantly improves overall survival in node-positive, ...

Overall survival outcomes in MATTERHORN trial support perioperative durvalumab plus chemotherapy as standard of care.

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...